ABOUT
The objective of this survey is to better understand the challenges of post-approval changes for nasal suspension and solution products when manufacturers of new drugs and generic products need to make changes in products after approvals of the applications. The results of the survey will be used by PQRI to identify topics for further discussion, research, and or potential workshops. The results of this survey will also be shared with FDA, which is a member of PQRI, for awareness of challenges with post-approval changes for nasal suspension and solution products.
INSTRUCTIONS
This survey is being conducted according to PQRI’s Antitrust Guidelines. Please do NOT disclose names of any compounds, partners (e.g., companies, contractors, vendors, universities, or other collaborators), or other proprietary information. Please do not disclose any information that could identify a study subject, patient, investigator, healthcare provider, or consumer.
Please ensure that you have all necessary permissions and approvals from your company to respond to this survey and do NOT disclose any information your company would not want disclosed, even if in a form not attributable to your company.
SAVING THE SURVEY FOR LATER
If you need to stop the survey for any reason and wish to complete it later, you can save your responses and pick up where you left off. To save and exit, click the "Save and Continue Later" option displayed in the black bar at the top of the survey browser window. You will be prompted to enter your email address and will receive a unique link, which will allow you to complete your responses at a later time.
SURVEY DEADLINE
Please provide your feedback by
Sept 30, 2024.
Questions about the administration of or content within this survey may be directed to PQRI's Secretariat (
Jillian.Brady@faegredrinker.com).